These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 20129455

  • 1. [The renin-angiotensin system in hypertension and in cardiovascular and renal diseases: highlights of the World Congress of Nephrology 2009]].
    Romet M.
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H10-3. PubMed ID: 20129455
    [No Abstract] [Full Text] [Related]

  • 2. [Debate concerning the optimal blockage of the renin-angiotensin system].
    Choukroun G.
    Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
    [No Abstract] [Full Text] [Related]

  • 3. [Overview of the RAAS in renal damage and hypertension].
    Yamamoto T, Nishiyama A.
    Nihon Jinzo Gakkai Shi; 2010 Jan; 52(2):87-91. PubMed ID: 20415226
    [No Abstract] [Full Text] [Related]

  • 4. [The prorenin receptor].
    Bracquart D, Cousin C, Contrepas A, Nguyen G.
    J Soc Biol; 2009 Jan; 203(4):303-10. PubMed ID: 20122388
    [Abstract] [Full Text] [Related]

  • 5. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
    Mansur SJ, Hage FG, Oparil S.
    Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system.
    Balakumar P, Jagadeesh G.
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):570-9. PubMed ID: 21108514
    [Abstract] [Full Text] [Related]

  • 7. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 8. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
    Nilsson PM, Cifkova R, Kjeldsen SE.
    J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
    [No Abstract] [Full Text] [Related]

  • 9. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
    Bakris GL.
    J Clin Hypertens (Greenwich); 2007 Jun; 9(6):413-5. PubMed ID: 17541325
    [No Abstract] [Full Text] [Related]

  • 10. Renin inhibition--benefit beyond hypertension control.
    Kher V.
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [Abstract] [Full Text] [Related]

  • 11. Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
    Mallat SG.
    Cardiovasc Diabetol; 2013 Jul 19; 12():108. PubMed ID: 23866091
    [Abstract] [Full Text] [Related]

  • 12. Direct renin inhibitors: ONTARGET for success?
    Pasha Y, Gusbeth-Tatomir P, Covic A, Goldsmith D.
    Int Urol Nephrol; 2009 Jul 19; 41(2):341-55. PubMed ID: 19296235
    [Abstract] [Full Text] [Related]

  • 13. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct 19; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 14. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
    Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM.
    Am J Hypertens; 2013 May 19; 26(5):583-90. PubMed ID: 23459599
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
    Morihira M, Kikuchi K, Nakagawa N, Fujino T, Hasebe N.
    Nihon Jinzo Gakkai Shi; 2009 May 19; 51(4):451-5. PubMed ID: 19601552
    [No Abstract] [Full Text] [Related]

  • 16. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW.
    South Med J; 2009 Dec 19; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract] [Full Text] [Related]

  • 17. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M.
    Dtsch Med Wochenschr; 2012 Nov 19; 137(48):2498. PubMed ID: 23168983
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Rational of the use of aliskiren in hypertension and beyond.
    Westermann D, Savvatis K, Schultheiss HP, Tschöpe C.
    Minerva Cardioangiol; 2009 Dec 19; 57(6):761-72. PubMed ID: 20019651
    [Abstract] [Full Text] [Related]

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 19; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.